Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

597 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
AKT and cancer--is it all mTOR?
Rosen N, She QB. Rosen N, et al. Cancer Cell. 2006 Oct;10(4):254-6. doi: 10.1016/j.ccr.2006.10.001. Cancer Cell. 2006. PMID: 17045203
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI. Morris MJ, et al. Among authors: rosen n. Clin Cancer Res. 2002 Mar;8(3):679-83. Clin Cancer Res. 2002. PMID: 11895895 Clinical Trial.
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. Solit DB, et al. Among authors: rosen n. Clin Cancer Res. 2002 May;8(5):986-93. Clin Cancer Res. 2002. PMID: 12006510
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Münster PN, Marchion DC, Basso AD, Rosen N. Münster PN, et al. Among authors: rosen n. Cancer Res. 2002 Jun 1;62(11):3132-7. Cancer Res. 2002. PMID: 12036925
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.
Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Basso AD, et al. Among authors: rosen n. J Biol Chem. 2002 Oct 18;277(42):39858-66. doi: 10.1074/jbc.M206322200. Epub 2002 Aug 9. J Biol Chem. 2002. PMID: 12176997
17AAG: low target binding affinity and potent cell activity--finding an explanation.
Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. Chiosis G, et al. Among authors: rosen n. Mol Cancer Ther. 2003 Feb;2(2):123-9. Mol Cancer Ther. 2003. PMID: 12589029
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. Huron DR, et al. Among authors: rosen n. Clin Cancer Res. 2003 Apr;9(4):1267-73. Clin Cancer Res. 2003. PMID: 12684394
597 results
Jump to page
Feedback